Track Hedge Funds Using 13F Filings

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of Security	Transaction Date	2a. Deemed Execution Date	Transaction Code	Shares	Acquired or Disposed	Price per share	5. Amount of Securities Beneficially Owned Following Reported Transaction	6. Ownership Form Direct or Indirect	Nature of Indirect Ownership
COMMON STOCK	2019-11-11		M	6,573	a	$45.45	36,640	direct
COMMON STOCK	2019-11-11		S	6,573	d	$118.15	30,067	direct

Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security	Conversion or Exercise Price of Derivative Security	Transaction Date	Deemed Execution Date	Transaction Code	Number of Derivative Securities Acquired (A) or Disposed of (D)	Date Exercisable	Expiration Date	Title and Amount of Securities Underlying Derivative Security	Price of Derivative Security	Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I)	Nature of Indirect Beneficial Ownership
NON-QUALIFIED STOCK OPTION (RIGHT TO BUY)	45.45	2019-11-11	deemed execution date	M	6,573 (d)	2014-07-24	2020-07-24	common stock 6,573	$45.45	0	direct

Footnotes
ID	footnote
f1	this number includes unvested restricted stock units previously reported.
f2	the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $118.00 to $118.64, inclusive. the reporting person undertakes to provide to haemonetics corporation ("haemonetics"), any security holder of haemonetics, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this form 4.
f3	grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant.

Form Type: 4